Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)
| 51.51 Delayed Data As of 3:59pm ET |  +0.26 / +0.51%Today’s Change | 33.36 Today|||52-Week Range 68.68 | +11.18% Year-to-Date |
Latest RARE News | Press Releases
| Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study 11:14am / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 51.25 |
| Today’s open | 54.44 |
| Day’s range | 50.85 - 54.98 |
| Volume | 37,937 |
| Average volume (3 months) | 616,329 |
| Market cap | $3.6B |
Data as of 3:59pm ET, 06/06/2023
Growth & Valuation
| Earnings growth (last year) | -51.09% |
| Earnings growth (this year) | +19.33% |
| Earnings growth (next 5 years) | +86.06% |
| Revenue growth (last year) | +3.39% |
| P/E ratio | NM |
| Price/Sales | 8.92 |
| Price/Book | 10.10 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CYTKCytokinetics Inc | -0.29 | -0.76% |
| ---- | ||
| FOLDAmicus Therapeutics ... | +0.30 | +2.46% |
| RETAReata Pharmaceutical... | +1.85 | +2.01% |
Data as of 4:00pm ET, 06/06/2023
Financials
| Next reporting date | August 3, 2023 |
| EPS forecast (this quarter) | -$2.07 |
| Annual revenue (last year) | $363.3M |
| Annual profit (last year) | -$707.4M |
| Net profit margin | -194.71% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Novato, California |
Forecasts
